This federal Project Grant award of $2,542,500.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will develop novel econometric methods and a unified framework for integrating real-world evidence (RWE) into the analysis of inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. The project will evaluate multiple maximum likelihood estimation (MLE) approaches combined with propensity...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the CFDA 93.279 Drug Use and Addiction Research Programs, aims to determine the extent to which cardiovascular disease (CVD) affects individuals with opioid use disorder (OUD) and how patients, providers, and payers can prevent CVD in this population. The $189,500 award, granted to the University of Pittsburgh, will be used to: 1) examine the relationship between OUD and time to major adverse...
This federal Project Grant award of $459,045, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study to modify the Opioid Use Disorder (OUD) Cascade of Care model to better reflect the current landscape of OUD treatment delivery. The RAND Corporation, a nonprofit global policy think tank, is the prime awardee on this 2-year grant with a period of performance from September 30, 2024 to September 29, 2026. The key...
This $385,000 federal Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a comprehensive analysis of treatment patterns, outcomes, and predictive factors for patients with co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD). The research aims to assess the effectiveness of integrated treatment approaches, including first-line OUD and AUD medications as well as glucagon-like peptide-1...
This $1,377,306 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a multi-jurisdictional study to transform the evidence base on the prevalence of opioid use disorder (OUD) and the impact of opioid agonist treatment (OAT) as a strategy to prevent opioid-related harms. The study, led by the University of New South Wales in Australia, will leverage data linkages across sites in the U.S. (Rhode Island,...
This Project Grant award for $144,362.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to evaluate a pharmacist-integrated model of opioid use disorder (OUD) treatment in primary care settings to increase naloxone co-prescribing. The research aims to: 1) describe federal, state, and clinic-level policies and interventions impacting naloxone co-prescribing, 2) investigate care team knowledge and attitudes...
The National Institute on Drug Abuse (NIDA) awarded a $177,170 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Massachusetts Medical School (UMass Medical) for the "Implementation of Medications for Opioid Use Disorder in Massachusetts Jails" project. The funding will support a mixed-methods study to analyze the implementation of medications for opioid use disorder (MOUD) treatment in Massachusetts county jails. The research aims...
This $1,499,606 Project Grant award was issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The primary awardee, Dartmouth-Hitchcock Clinic, will lead a multidisciplinary research project to characterize health outcomes and disparities in children born to parents with opioid use disorder, as well as identify protective health system factors. Key objectives include: 1) examining variation in diagnosis rates of neonatal opioid...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), especially those using fentanyl. The key objectives of this 4-year project are to: 1) identify barriers to successful LDI completion through qualitative interviews, 2)...
This $1,534,938 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a randomized controlled trial to evaluate an immersive mindfulness virtual reality (VR) intervention for chronic pain and opioid use disorder (OUD) in opioid treatment programs. The grant will support enrollment and randomization of 185 participants with chronic pain and OUD at opioid treatment programs in the Bronx, New York to receive...
This Project Grant award of $1,329,844 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to assess the causal impact and equity effects of the New York State Medicaid Value-Based Payment (VBP) policy on opioid use disorder (OUD)-related outcomes, including service use, quality, overdose, and healthcare costs.
The research team from the Cambridge Public Health Commission, doing business as the Cambridge Health Alliance, will leverage a natural experiment to evaluate the overall effects of the VBP policy as well as examine how individual, area, and policy-level factors may influence the policy's impact on OUD-related outcomes. The findings are expected to provide valuable evidence to inform VBP policy implementation in New York and other states, with the goal of improving healthcare access and equity for individuals with OUD.